What limits burst release in subcutaneous in-situ forming implants based on RESOMER RG 756 S?

Burst release is governed by the rate of solvent exchange across the forming implant boundary. RESOMER RG 756 S is dissolved in N-methyl-2-pyrrolidone at 30–50% w/w. The solution viscosity at 25°C ranges from 2,000 mPa·s to 15,000 mPa·s depending on polymer concentration and residual moisture. When injected into subcutaneous tissue, water influx causes the polymer to precipitate. The precipitated shell grows inward as the solvent diffuses outward. If the polymer concentration is below 35% w/w, the shell is porous and burst exceeds 20% of total drug load within 24 h. At 45% w/w polymer, burst is typically reduced below 10%. However, injection force through a 21 G needle rises non-linearly above 45% w/w.

Formulation with a hydrophobic co-solvent lowers water miscibility. Benzyl alcohol or ethyl benzoate can be added at 5–10% w/w of the solvent blend. This slows water penetration but extends the initial solvent loss period. The depot may remain soft for 1–3 h after injection. The final release duration is influenced by the 75:25 lactide-to-glycolide ratio. Mass loss is slower than a 50:50 PLGA because the higher lactide content reduces glycolic acid autocatalysis. Release from a 45% w/w depot may extend to 60–90 days for hydrophobic small molecules. Published data for this specific configuration is limited, so release must be verified by USP <711> Apparatus 4 with a suitable sink volume.

Manufacturing uses vacuum planetary mixing under dry nitrogen. The polymer and solvent are mixed for 12–24 h at 25°C until a clear solution forms. The solution is degassed by centrifugation at 1,500×g for 10 min. Filling into pre-filled syringes occurs in an isolator under ISO Class 5 conditions. Residual solvent testing follows ICH Q3C. NMP is Class 2 with a PDE of 5.3 mg/day and a limit of 530 ppm. DMSO is Class 3 with a PDE of 50 mg/day. The terminal product is a sterile, viscous implant-forming solution. It solidifies in situ and is used for subcutaneous or periodontal delivery of small molecules. Local tolerance is assessed by ISO 10993-6 implantation studies. The risk of burst release remains a critical process challenge. It is controlled by polymer concentration, solvent ratio, and tissue fluid exchange rate.

Long-acting parenteral depot manufacture using RESOMER RG 756 S typically begins with a water-in-oil-in-water double emulsion when the API is a peptide or protein. The polymer is dissolved in dichloromethane at 5–25% w/v. The drug solution is dispersed at 10,000–20,000 rpm in a rotor-stator mixer to form the primary emulsion. The primary emulsion is then added to an aqueous poly(vinyl alcohol) solution at 1–2% w/v saturated with dichloromethane. A secondary emulsion forms under 3,000–10,000 rpm using a Silverson L5T or IKA T25 homogenizer. Droplet size follows the Weber number relationship. It is controlled by continuous-phase viscosity and rotor peripheral speed. Batch-to-batch span values below 1.5 require jacket temperature control at 20–25°C.

Solvent extraction proceeds by transfer into a 10–20× volume of cold distilled water. Stirring at 300–500 rpm for 4–6 h hardens the microspheres. Residual dichloromethane is reduced below 600 ppm as required by ICH Q3C Class 2. PVA removal is performed by tangential flow filtration with 0.2 µm cassettes and 5–10 diafiltration volumes. The microspheres are then lyophilized. The freeze-drying cycle includes freezing at -40°C, primary drying at -20°C and 100 µbar for 24 h, and secondary drying at 20°C and 50 µbar for 12 h. Final cake moisture is controlled below 2.0% w/w because residual water accelerates PLGA ester hydrolysis during storage.

Release testing follows USP <711> Apparatus 4 with a flow-through cell. Sterility is verified by USP <71>. Bacterial endotoxins are measured by USP <85>. Elemental impurities are assessed by ICH Q3D. Terminal sterilization by gamma irradiation above 25 kGy reduces molecular weight through chain scission and is avoided for peptide-loaded depots. Aseptic filling under ISO Class 5 conditions is therefore specified. The final dosage form is reconstituted in an aqueous vehicle containing sodium carboxymethylcellulose 0.5% w/v, mannitol 4% w/v, and polysorbate 20 0.1% w/v. The suspension is administered by subcutaneous or intramuscular injection through a 19–21 G thin-wall needle.

For intravenous and pulmonary delivery, sterile-filterable PLGA nanoparticles can be prepared by confined impinging jet mixing. An organic phase contains RESOMER RG 756 S at 10–50 mg/mL in acetone. The aqueous phase contains poloxamer 188 at 0.1–0.5% w/v in purified water. The two streams collide in a multi-inlet vortex mixer at 20–100 mL/min per stream. Mixing occurs on a millisecond timescale. Particle nucleation is driven by supersaturation of the polymer in the anti-solvent. The resulting nanoparticles have a mean diameter of 100–220 nm and polydispersity index below 0.2 when the organic-to-aqueous flow ratio is 1:5. Larger particles above 250 nm foul sterile filters. The dispersion is immediately diluted with water to slow Ostwald ripening.

Acetone is removed by rotary vacuum distillation at 40°C and 150 mbar. Diafiltration against purified water removes free surfactant. A 300 kDa tangential flow filtration cassette is used. The nanoparticles are then sterile-filtered through a 0.22 µm PVDF membrane. Filter pressure should remain below 0.5 bar to avoid disrupting the particles. Lyophilization requires a cryoprotectant. Trehalose at 5–10% w/w of the dispersion is added before freezing. The cake is dried at -30°C primary and 25°C secondary with a chamber pressure of 50–100 µbar. The terminal product is a sterile, lyophilized nanoparticle cake for intravenous or pulmonary delivery after reconstitution.

Residual acetone is controlled below 5000 ppm as an ICH Q3C Class 3 solvent. If acetonitrile is used instead of acetone, the limit is 410 ppm and the PDE is 4.1 mg/day. Hemocompatibility is evaluated by ISO 10993-4. Subvisible particulate matter is controlled by USP <787>. Endotoxin is controlled by USP <85>. Drug loading for hydrophobic small molecules is typically 1–10% w/w of the polymer. Higher loading may cause burst release above 30% in the first 6 h. The process is limited by mixing energy dissipation. Scale-up beyond 500 mL/min total flow requires parallel mixing heads to maintain turbulent Reynolds numbers above 1,000.

Hot-melt extruded implantable rods demand tight processing control

Hot-melt extrusion of RESOMER RG 756 S is performed on a co-rotating twin-screw extruder with an L/D ratio of 25:1 to 40:1. The polymer is pre-dried at 40°C and 0.1 mbar for 24 h because moisture above 0.1% w/w accelerates ester hydrolysis during extrusion. The dry polymer is blended with micronized API at 5–30 wt% in a Turbula mixer for 15–30 min. Triethyl citrate can be added at 5–10 wt% to lower melt viscosity and reduce shear heating. The blend is fed into the extruder at 1–5 kg/h under nitrogen purge. Barrel zone temperatures are set to 25°C, 60°C, 80°C, 90°C, 95°C, and 85°C at the die. Screw speed is kept between 100–200 rpm. Residence time is 2–5 min. Torque should remain below 70% of drive capacity.

Molecular weight retention is a primary process indicator. The polymer is analyzed by gel permeation chromatography against polystyrene standards. A reduction in weight-average molecular weight below 20% of the starting value indicates excessive thermal or hydrolytic degradation. Melt viscosity should be monitored by capillary rheometry at 100°C rather than fixed as a single release criterion. The die pressure ranges from 20–80 bar depending on die diameter and throughput. Extrudates are cooled on a stainless steel belt at 10–15°C and cut into rods of 1.0–3.0 mm diameter and 10 mm length. The rods are placed in foil pouches with desiccant. The final implant is used for subcutaneous or intratumoral insertion. Drug release follows bulk erosion of the 75:25 PLGA matrix rather than surface erosion.

Process failures include die swelling, melt fracture, and discoloration above 120°C. Screw speeds above 300 rpm generate local shear heating that produces acidic degradation products. These acidic products can catalyze further hydrolysis of the polymer. Therefore, the extruder must be equipped with a vacuum vent to remove residual moisture and volatile monomers. The terminal product must meet ISO 10993-5 for cytotoxicity. Residual monomers are controlled by the manufacturer specification. Elemental impurities are assessed by ICH Q3D. The extruder contact surfaces are cleaned with hot alkaline detergent and passivated. Cleaning validation is performed by swab sampling and total organic carbon analysis.

In closed-loop ultrasonic spray coating, RESOMER RG 756 S is used when sustained drug release is required at a tissue-implant interface. The polymer is dissolved at 1–5% w/v in a solvent blend of acetone and methyl ethyl ketone at 70:30. The API is added at 0.1–1.0% w/v. The solution viscosity is maintained below 5 mPa·s to allow atomization. An ultrasonic nozzle operating at 40–120 kHz produces droplets with a median diameter below 50 µm. The liquid flow rate is 0.1–1.0 mL/min. Atomization pressure is 0.5–2.0 bar. The substrate is held at 35–50°C on a heated vacuum chuck. A spray standoff of 5–20 mm controls drying time. Each pass deposits 0.1–0.5 µm of coating. Multi-layer coating builds to 2–10 µm total thickness.

Residual solvent removal is performed under vacuum at 50°C and 0.1 mbar for 24 h. Acetone and methyl ethyl ketone are ICH Q3C Class 3 solvents with a limit of 5000 ppm. Coating delamination occurs when thickness exceeds 15 µm or when the substrate undergoes strain greater than 5% during deployment. Oxygen plasma treatment at 100 W for 5 min increases surface wettability and improves adhesion. A silane adhesion promoter can be applied to metallic substrates before coating. Cracking is observed when the coating is dried too rapidly at high humidity. Relative humidity should remain below 40% during spraying to prevent condensation and phase separation.

The coated implant is tested for cytotoxicity by ISO 10993-5. Sensitization is evaluated by ISO 10993-10. Release is measured by USP <711> Apparatus 7 with reciprocating holders. The coating matrix degrades by hydrolysis of ester bonds. The 75:25 lactide-to-glycolide ratio gives a slower degradation profile than 50:50 PLGA. Ethylene oxide sterilization can plasticize the coating and alter release kinetics. Electron beam sterilization above 25 kGy may induce chain scission. The coating is therefore processed under aseptic conditions whenever possible. The terminal application includes drug-eluting orthopedic trauma hardware and bioresorbable scaffolds used in vascular tissue engineering.

When RG 756 S is solvent-cast into periodontal films and ophthalmic inserts

After dissolution in ethyl acetate, RESOMER RG 756 S is cast into thin monolithic dosage forms. The polymer is dissolved in ethyl acetate at 15–30% w/v. The API is added at 10–30% w/w of the polymer mass. The solution is filtered through a 5 µm membrane before casting. A knife coater with a gap of 200–1,000 µm deposits the solution onto a polyester release liner. The wet film is dried at ambient temperature for 24 h under a fume hood. Final drying is performed under vacuum at 40°C and 50 mbar for 12 h. Residual ethyl acetate is controlled below 5000 ppm as an ICH Q3C Class 3 solvent. The dried film thickness is 100–500 µm. It is die-cut into 5×5 mm periodontal chips or 3×1 mm ocular inserts.

Mechanical properties depend on residual solvent content and plasticizer level. Films with low residual solvent are brittle and may fracture during cutting. A plasticizer such as triethyl citrate at 5–10 wt% increases flexibility but accelerates release. For ophthalmic inserts, the polymer must dissolve or erode slowly in tear fluid. The 75:25 PLGA grade degrades over several weeks. For periodontal chips, the insert is placed into the periodontal pocket and delivers the drug locally. Release is tested by USP <711> Apparatus 5 paddle-over-disk or Apparatus 6 rotating cylinder. The dissolution medium is phosphate-buffered saline at pH 7.4 and 37°C. Antimicrobial actives like chlorhexidine gluconate at 10–20% w/w are common in this application.

Moisture absorption is a critical storage limitation. PLGA films absorb water at relative humidity above 60%. This triggers hydrolysis and reduces shelf life. The finished product is packaged in aluminum foil pouches with silica gel desiccant. Heat sealing is performed under nitrogen purge. The packaged product is tested for degradation products by HPLC. Cytotoxicity is evaluated by ISO 10993-5. Ophthalmic inserts must meet USP <771> for ophthalmic quality attributes. Sterility is verified by USP <71>. The manufacturing process is conducted in an ISO Class 5 environment when terminal sterilization is not feasible.